Investor Presentation - First Six Months of 2021
32
Investor presentation First six months of 2021
Novo Nordisk®
Novo Nordisk's core capabilities provide a competitive advantage
to continue to defeat diabetes
Engineering, formulating,
developing and delivering
protein-based treatments
Efficient large-scale
production of proteins
Global commercial reach and
leader in chronic disease care
Deep disease
understanding
Today: Oral solutions to
differentiate from
competition
Tomorrow: Expand oral
platforms and transformational
medicines via Novo Nordisk stem
cell platform
السمر
balo
Today: The world's
largest producer of
insulin and GLP-1
Tomorrow: Expand capacity by
completion of the US diabetes
API facility and continued
efficiency gains
|.000
② ५
Today: Global reach and
OzempicⓇ was the fastest
blockbuster in diabetes
Tomorrow: Continued rollout of
injectable diabetes portfolio and
launch of RybelsusⓇ
ه
D
Today: Provide value and
outcomes beyond HbA1c
for diabetes
Tomorrow: Normalise living with
diabetes supported by digital
solutions
API: Active pharmaceutical ingredient; HbA₁: Refers to glycated haemoglobin, which is the average blood glucose (sugar) levels for the last three monthsView entire presentation